New products
Abbott commercially rolls out Oncodetect MRD assay
Abbott has launched Oncodetect, a next-generation minimal residual disease (MRD) assay designed to detect circulating tumor DNA in patients with solid tumors. The assay enables early identification of cancer recurrence or progression through blood-based testing, expanding Abbott's oncology diagnostics portfolio.
The source
This brief is a MedIndexer summary of reporting by Medical Device Network. To read the full story, head to the source.
Read the full story at Medical Device Network